艾塞那肽与甘精胰岛素治疗血糖控制不佳2型糖尿病的临床对照研究
|
摘要
目的探讨艾塞那肽与甘精胰岛素治疗血糖控制不佳2型糖尿病的临床对照效果。方法选取海军总医院收治的血糖控制不佳2型糖尿病患者92例,按照随机数字表法分为艾塞那肽组和甘精胰岛素组各46例,比较两组患者的各项指标。结果两组患者的临床疗效比较,差异无显著性(P>0.05)。两组患者治疗前的体重指数差异均无显著性(P>0.05)。但治疗后艾塞那肽组体重指数较甘精胰岛素组明显降低(P<0.05)。两组患者治疗后的血糖控制情况均较治疗前有明显好转(P<0.05);甘精胰岛素组的空腹血糖控制水平明显优于艾塞那肽组(P<0.05);艾塞那肽组的餐后2小时血糖、糖化血红蛋白控制水平明显优于甘精胰岛素组(P<0.05);两组患者不良反应发生率比较,差异无显著性(P>0.05)。结论相对甘精胰岛素而言,艾塞那肽能更有效地降低患者体重指数,降低糖化血红蛋白和低血糖发生率,值得临床应用。
Objective To investigate the effect of exenatide and insulin glargine for poorly glycemic controlled in type 2 diabetes. Method 92 poor glycemic control patients with type 2 diabetes in the navy general hospital were chosen and divided into exenatide group and insulin glargine group, that each group has 46 cases. The clinical efficiency of the two groups were observed and compared, the changes of the body mass index, glycemic control, and the incidence of associated complications. Result The difference of the clinical curative effect between two groups was not statistically significant(P>0.05). Compared two groups' respective change of their body mass index between before and after treatment, there was no significant difference(P>0.05); the body mass index of exenatide group was lower than the insulin glargine after treatment(P<0.05). Glycemic control of two groups after treatment was greater than before treatment(P<0.05); the control of fasting plasma glucose of ins-ulin glargine group was better than exenatide group(P<0.05); the control of 2 hour plasma glucose and hemoglobin A1c of exenatide group was greater than the insulin glargine group(P<0.05). Compare the adverse reactions incidence of two groups of patients, there was no significant difference(P>0.05). Conclusion Relative to insulin glargine, exenatide can more effectively reduce body mass index, lower glycated hemoglobin, lower incidence of hypoglycemia, which is worth promoting in clinical practice.
Objective To investigate the effect of exenatide and insulin glargine for poorly glycemic controlled in type 2 diabetes. Method 92 poor glycemic control patients with type 2 diabetes in the navy general hospital were chosen and divided into exenatide group and insulin glargine group, that each group has 46 cases. The clinical efficiency of the two groups were observed and compared, the changes of the body mass index, glycemic control, and the incidence of associated complications. Result The difference of the clinical curative effect between two groups was not statistically significant(P>0.05). Compared two groups' respective change of their body mass index between before and after treatment, there was no significant difference(P>0.05); the body mass index of exenatide group was lower than the insulin glargine after treatment(P<0.05). Glycemic control of two groups after treatment was greater than before treatment(P<0.05); the control of fasting plasma glucose of ins-ulin glargine group was better than exenatide group(P<0.05); the control of 2 hour plasma glucose and hemoglobin A1c of exenatide group was greater than the insulin glargine group(P<0.05). Compare the adverse reactions incidence of two groups of patients, there was no significant difference(P>0.05). Conclusion Relative to insulin glargine, exenatide can more effectively reduce body mass index, lower glycated hemoglobin, lower incidence of hypoglycemia, which is worth promoting in clinical practice.
引文
[1]李晓敏.浅谈糖尿病的临床医学治疗与数据分析[J].中国继续医学教育,2015,7(7):55-56.
[2]世界卫生组织.关于糖尿病的十个事实[J].中国卫生政策研究,2013,6(10):35.
[3]沈蕾,裴育,巴建明.2014 ADA糖尿病指南要点解析[J].中国药物应用与监测,2015,12(1):1-4.
[4]李素君,周重楚.2型糖尿病治疗药物的新进展[J].医学综述,2013,19(14):2609-2612.
[5]孙逊.检验在糖尿病诊断中的临床应用[J].基础医学论坛,2015,19(9):1209-1210.
[6]王增义,崔晓红.老年2型糖尿病患者综合血糖控制目标管理进展[J].中国临床医生,2013,41(9):15-16.
[7]高志玲.1型糖尿病发病机制的研究[J].中国现代药物应用,2011,5(7):61-62.
[8]张霞.2型糖尿病的临床发病机制分析[J].齐齐哈尔医学院学报,2013,34(18):2673-2674.
[9]张冬梅.联合测定空腹血糖和糖化血清蛋白在糖尿病诊断中的临床价值[J].中国继续医学教育,2015,7(7):163-164.
[10]管大顺,刘爱梅,夏金花.影响糖尿病患者驾驭五驾马车的原因分析及护理干预[J].临床医药文献杂志,2014,1(10):1783-1784.
[11]周方方,张晓娜,朱琼.“五驾马车”在糖尿病健康教育中的应用探讨[J].糖尿病新世界,2014(10):73.
[12]刘芳,王显凤,刘松青.二型糖尿病治疗新药——利拉利汀的临床应用评价[J].中国医院药学杂志,2013,33(3):231-234.
[13]于可,赵冬.新诊断2型糖尿病应用艾塞那肽治疗的临床观察[J].中国医刊,2012,47(7):55-56.
[14]林洁欣,林武,於松达.艾塞那肽对2型糖尿病患者胰岛素分泌和胰岛素抵抗的影响[J].现代实用医学,2014,26(10):1300-1301.
[15]贺晖英,史长浩,国静雪,等.甘精胰岛素联合瑞格列奈治疗继发性失效的2型糖尿病临床观察[J].中国临床医生,2012,40(3):61-62.
[2]世界卫生组织.关于糖尿病的十个事实[J].中国卫生政策研究,2013,6(10):35.
[3]沈蕾,裴育,巴建明.2014 ADA糖尿病指南要点解析[J].中国药物应用与监测,2015,12(1):1-4.
[4]李素君,周重楚.2型糖尿病治疗药物的新进展[J].医学综述,2013,19(14):2609-2612.
[5]孙逊.检验在糖尿病诊断中的临床应用[J].基础医学论坛,2015,19(9):1209-1210.
[6]王增义,崔晓红.老年2型糖尿病患者综合血糖控制目标管理进展[J].中国临床医生,2013,41(9):15-16.
[7]高志玲.1型糖尿病发病机制的研究[J].中国现代药物应用,2011,5(7):61-62.
[8]张霞.2型糖尿病的临床发病机制分析[J].齐齐哈尔医学院学报,2013,34(18):2673-2674.
[9]张冬梅.联合测定空腹血糖和糖化血清蛋白在糖尿病诊断中的临床价值[J].中国继续医学教育,2015,7(7):163-164.
[10]管大顺,刘爱梅,夏金花.影响糖尿病患者驾驭五驾马车的原因分析及护理干预[J].临床医药文献杂志,2014,1(10):1783-1784.
[11]周方方,张晓娜,朱琼.“五驾马车”在糖尿病健康教育中的应用探讨[J].糖尿病新世界,2014(10):73.
[12]刘芳,王显凤,刘松青.二型糖尿病治疗新药——利拉利汀的临床应用评价[J].中国医院药学杂志,2013,33(3):231-234.
[13]于可,赵冬.新诊断2型糖尿病应用艾塞那肽治疗的临床观察[J].中国医刊,2012,47(7):55-56.
[14]林洁欣,林武,於松达.艾塞那肽对2型糖尿病患者胰岛素分泌和胰岛素抵抗的影响[J].现代实用医学,2014,26(10):1300-1301.
[15]贺晖英,史长浩,国静雪,等.甘精胰岛素联合瑞格列奈治疗继发性失效的2型糖尿病临床观察[J].中国临床医生,2012,40(3):61-62.